XORTX Therapeutics Inc Stock
-
Your prediction
Pros and Cons of XORTX Therapeutics Inc in the next few years
Pros
Cons
Performance of XORTX Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| XORTX Therapeutics Inc | - | - | - | - | - | - | - |
| Arctic Star Exploration Corp. | - | 11.111% | 25.000% | -28.571% | 100.000% | -89.362% | -87.531% |
| Romios Gold Res Inc. | 700.000% | -85.714% | -85.714% | -95.238% | -92.857% | -98.077% | -97.619% |
| Hannan Metals Ltd. | 0.690% | 8.527% | 0.000% | 48.541% | 137.288% | 2.941% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In reviewing the financials of XORTX in the Metals & Mining industry, a few initial impressions emerge. The company has been experiencing growing total assets and stockholder equity in recent years. However, the company seems to be reporting continuous net losses and negative cash flows from operating activities. A deeper examination of the financial statements is necessary to gain a complete understanding of the strengths and weaknesses of XORTX.
Increasing Total Assets: From 2020 to 2022, the company's total assets have increased significantly, going from CAD 2.29 million to CAD 16.75 million. This growth demonstrates the company's ability to accumulate resources and indicates an expanding operational scale.
Higher Stockholder Equity: The total stockholder equity has been on a rise over these years. It has grown from CAD 1.25 million in 2020 to CAD 9.46 million in 2022. This increase suggests a stable financial position for the company.
Comments
News
XORTX Clarifies Timing for Share Consolidation
CALGARY, AB – November 10, 2023 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on
XORTX Announces Share Consolidation
CALGARY, AB - November 8, 2023 - XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023
- Preclinical Findings Help Clarify and Reinforce the Role of Uric Acid in the Pathogenesis of Polycystic Kidney Disease and the Potential of XORTX’s Proprietary Formulation of